Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2011

View Archived Issues

Highly selective mGlu4 receptor positive allosteric modulator discovered

Interim data presented from the first-in-human trial of MABp1 in advanced tumors

Action Pharma presents data from phase II trial of AP-214

University of Cambridge and Elan launch center for research focused on neurodegenerative disorders

Phase III data support lixivaptan therapy in euvolemic hyponatremia

New inhibitor of dual specificity protein kinase TTK shows promising preclinical antitumor activity

Allergy Therapeutics announces Pollinex Quattro submissions in Germany and the U.S.

Yakult gains approval for use of Elplat in new indication in Japan

PharmaGap advances anticancer liposomal formulation preparations

New vasopressin V1A receptor antagonists disclosed by Roche

Novel tumor-specific promoters designed by Korean team

Onglyza obtains E.U. approval for saxagliptin combination therapy

Novel lysosomal Pro-X carboxypeptidase inhibitors prepared by Merck & Co.

Pharmaleads announces promising phase I results of PL-37

Roche synthesizes new Mdm2 inhibitors

Exelixis signs CRADA for cabozantinib with National Cancer Institute

Shionogi patents novel cephems with antibacterial activity

SuppreMol begins SM-101 dosing in SMILE study

FDA gives clearance for phase IIa study of AEZS-130

Micromet begins study of blinatumomab in acute lymphoblastic leukemia

FDA approves Tekmira Pharmaceuticals' TKM-Ebola IND

Immunicum gains clearance for trial of dendritic cell-based anticancer vaccine

Gilead obtains European approval for Eviplera

European Commission approves Edurant for treatment-naive adults with HIV-1

Akebia begins dosing in first-in-man phase I AKB-9778 study

DMC recommends to continue Celsion's phase III HEAT study

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...